Alimta (Molecule of the Month for December 2005)
ALIMTA as a single-agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after prior chemotherapy. Alimta when given with cisplatin, is the first and only chemotherapy drug to be approved for the treatment of patients with malignant pleural mesothelioma (MPM) - which is a cancer of the linings of the lungs, rather than a cancer that forms in the lungs. The cancer is comonly caused by asbestos.
Chemotherapy consists of treatment with one or more anticancer drugs that destroy cancer cells. Alimta works by interfering with a crucial process that allows cancer cells to reproduce and spread. Specifically, Alimta works by stopping the production of three enzymes that are required to feed the cancer cell.
Formal Chemical Name (IUPAC)
Update by Karl Harrison
(Molecule of the Month for December 2005 )